Skip to main content
SpringerLink
Log in

Current Treatment of Dyslipidemia: A New Paradigm for Statin Drug Use and the Need for Additional Therapies

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Coronary heart disease (CHD) is the leading cause of death in most countries, with the high prevalence currently driven by dual epidemics of obesity and diabetes. Statin drugs, the most effective, evidence-based agents to prevent and treat this disease, have a central role in management and are advised in all published guidelines. The 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol and assessment guidelines (‘new ACC/AHA guidelines’) emphasized global cardiovascular (CV) risk reduction as opposed to targeting low-density lipoprotein-cholesterol (LDL-C) levels, stressed the use of statins in two dose intensities, utilized a new risk calculator using pooled cohort equations, and lowered the risk cutoff for initiation of statin therapy. Although there were major strengths of the new ACC/AHA guidelines, substantial controversy followed their release, particulars of which are discussed in this review. They were generally regarded as improvements in an ongoing transition using evidenced-based data for maximum patient benefit. Several guidelines, other than the ACC/AHA guidelines, currently provide practitioners with choices, some depending on practice locations. Cholesterol control with statin drugs is used in all paradigms. However, some patients respond inadequately, approximately 15 % are intolerant, and other factors prevent attaining cholesterol goals in as many as 40 % of patients. Even after treatment, substantial residual risk for ongoing major events remains. Another readily available modality that can rival statin drugs in effectiveness is vast improvement in diet and lifestyle within the general population; however, despite great effort, existing programs to implement such changes have failed. Hence, despite unrivaled success, there is great need for additional drugs to prevent and treat CHD, whether as monotherapy or in combination with statin drugs. New American guidelines do not discuss or recommend any nonstatin drugs for CHD, and the US FDA has moved away from approving drugs based solely on changes in surrogates in the absence of clinical outcomes trials. Both have significantly altered the realities of developing pharmacotherapies and cardiology practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Keller A, Graefen A, Ball M, Matzas M, Boisguerin V, Maixner F, et al. New insights into the Tyrolean Iceman’s origin and phenotype as inferred by whole-genome sequencing. Nat Commun. 2012;3:698.

    Article  PubMed  Google Scholar 

  2. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.

    Article  CAS  PubMed  Google Scholar 

  3. Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol. 2014;11:276–89.

    Article  PubMed  Google Scholar 

  4. Kones R. Is prevention a fantasy, or the future of medicine? A panoramic view of recent data, status, and direction in cardiovascular prevention. Ther Adv Cardiovasc Dis. 2011;5:51–61.

    Article  Google Scholar 

  5. Grundy SM, Cleeman JI, Merz CNB, Brewer HB Jr, Clark LT, Hunninghake DB, For the Coordinating Committee of the National Cholesterol Education Program, et al. Summary of implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Arterioscler Thromb Vasc Biol. 2004;24:1329–30.

  6. Jaffer FA, O’Donnell CJ, Larson MG, et al. Age and sex distribution of subclinical aortic atherosclerosis: a magnetic resonance imaging examination of the Framingham Heart Study. Arterioscler Thromb Biol. 2002;22:849–54.

    Article  CAS  Google Scholar 

  7. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353:89–92.

    Article  CAS  PubMed  Google Scholar 

  8. Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162:1867–72.

    Article  PubMed  Google Scholar 

  9. Wilkins JT, Ning H, Berry J, Zhao L, Dyer AR, Lloyd-Jones DM. Lifetime risk and years lived free of total cardiovascular disease. JAMA. 2012;308:1795–801.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–39.

    Article  PubMed  Google Scholar 

  11. Ferrières J. Effects on coronary atherosclerosis by targeting low-density lipoprotein cholesterol with statins. Am J Cardiovasc Drugs. 2009;9:109–15.

    Article  PubMed  Google Scholar 

  12. Zhou Q, Liao JK. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des. 2009;15:467–78.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol. 2011;301:H287–96.

    Article  CAS  PubMed  Google Scholar 

  14. Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol. 2000;35:1–10.

    Article  CAS  PubMed  Google Scholar 

  15. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.

  16. Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL cholesterol with ststin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90.

  17. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46:1225–8.

    Article  PubMed  Google Scholar 

  18. Kones R, Rumana U. Cardiovascular prevention: components, levels, early origins, and metrics. Hosp Pract. 2014;42(3):84–95.

    Article  Google Scholar 

  19. Ray KK, Cannon, Cairns R, Morrow DA, Rifai N, Kirtane AJ, PROVE IT-TIMI 22 Investigators, et al. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 Trial. J Am Coll Cardiol. 2005;46:1417–24.

  20. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504.

    Article  CAS  PubMed  Google Scholar 

  21. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ. 1991;303:276–82.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. O’Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: Lower is better and physiologically normal. J Am Coll Cardiol. 2004;43:2142–6.

    Article  PubMed  Google Scholar 

  23. O’Keefe JH Jr, Cordain L. Cardiovascular disease resulting from a diet and life-style at odds with our Paleolithic genome: how to become a 21st-century hunter-gatherer. Mayo Clin Proc. 2004;79:101–8.

    Article  PubMed  Google Scholar 

  24. Forrester JS. Redefining normal low-density lipoprotein cholesterol: a strategy to unseat coronary disease as the nation’s leading killer. J Am Coll Cardiol. 2010;56:630–6.

    Article  PubMed  Google Scholar 

  25. Hochholzer W, Giugliano RP. Lipid lowering goals: back to nature? Ther Adv Cardiovasc Dis. 2010;4:185–91.

    Article  CAS  PubMed  Google Scholar 

  26. Ramjee V, Jacobson TA. Intensifying statin therapy to maximize cardiovascular risk reduction: is 50 the new 70? Goals are getting old. Clin Lipidology. 2011;6:131–6.

    Article  CAS  Google Scholar 

  27. Nissen S, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, For the REVERSAL Investigators, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071–80.

  28. Benn M, Nordestgaard BG, Grande P, Schnorr P, Tybjærg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol. 2010;55:3833–42.

    Article  Google Scholar 

  29. Raal FJ, Stein EA. Targeting LDL: is lower better and is it safe? Best Pract Res Clin Endocrinol Metab. 2014;28:309–24.

    Article  PubMed  Google Scholar 

  30. Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a mendelian randomization analysis. J Am Coll Cardiol. 2012;60:2631–9.

    Article  CAS  PubMed  Google Scholar 

  31. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJP, For the JUPITER Study Group, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.

  32. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.

    Article  CAS  PubMed  Google Scholar 

  33. Macedo AF, Taylor FC, Casas JP, Adler A, Prieto-Merino D, Ebrahim S. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med. 2014;12:51.

    Article  PubMed Central  PubMed  Google Scholar 

  34. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8:373–418.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Jacobson TA, The NLA. Task force on statin safety—2014 update. J Clin Lipidol. 2014;8(Suppl):S1–4.

    Article  Google Scholar 

  36. Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158:526–34.

    Article  PubMed Central  PubMed  Google Scholar 

  37. Chen YH, Feng B, Chen ZW. Statins for primary prevention in cardiovascular and cerebrovascular events in diabetic patients without established cardiovascular disease: a meta-analysis. Exp Clin Endocrinol Diabetes. 2012;120:116–20.

    Article  CAS  PubMed  Google Scholar 

  38. Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013;111:1123–30.

    Article  CAS  PubMed  Google Scholar 

  39. Hu M, Cheung BMY, Tomlinson B. Safety of statins. Ther Adv Drug Saf. 2012;3:133–44.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. An assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol. 2014;8:S58–71.

    Article  PubMed  Google Scholar 

  41. Hoffman KB, Kraus C, Dimbil M, Golomb BA. A survey of the FDA’s AERS database regarding muscle and tendon adverse events linked to the statin drug class. PLoS One. 2012;7:e42866.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 2002;110:285–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Sakamoto K, Wada I, Kimura J. Inhibition of Rab1 GTPase and endoplasmic reticulum-to-Golgi trafficking underlies statin’s toxicity in rat skeletal myofibers. J Pharmacol Exp Ther. 2011;338:62–9.

    Article  CAS  PubMed  Google Scholar 

  44. Barylski M, Nikolic D, Banach M, Toth PP, Montalto G, Rizzo M. Statins and new-onset diabetes. Curr Pharm Des. 2014;20:3657–64.

    Article  CAS  PubMed  Google Scholar 

  45. Mallinson JE, Marimuthu K, Murton A, Selby A, Smith K, Constantin-Teodosiu D, et al. Statin myalgia is not associated with reduced muscle strength, mass or protein turnover in older male volunteers, but is allied with a slowing of time to peak power output, insulin resistance and differential muscle mRNA expression. J Physiol. 2015;593:1239–57.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD. Molecular basis of statin-associated myopathy. Atherosclerosis. 2009;202:18–28.

    Article  CAS  PubMed  Google Scholar 

  47. Sirvent P, Mercier J, Vassort G, Lacampagne A. Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle. Biochem Biophys Res Commun. 2005;329:1067–75.

    Article  CAS  PubMed  Google Scholar 

  48. Sirvent P, Mercier J, Lacampagne A. New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol. 2008;8:333–8.

    Article  CAS  PubMed  Google Scholar 

  49. Chapman MJ, Carrie A. Mechanisms of statin-induced myopathy: a role for the ubiquitin–proteasome pathway? Arterioscler Thromb Vasc Biol. 2005;25:2441–4.

    Article  CAS  PubMed  Google Scholar 

  50. Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol. 2006;291:C1208–12.

    Article  CAS  PubMed  Google Scholar 

  51. Zorgiebel T, Weigl L, Genth H, Hohenegger M. Activation of RhoB in simvastatin-induced apoptosis of differentiated human skeletal muscle cells. BMC Pharmacol. 2007;7(Suppl 2):A16.

    Article  Google Scholar 

  52. Smith R, Solberg R, Jacobsen LL, Voreland AL, Rustan AC, et al. Simvastatin inhibits glucose metabolism and legumain activity in human myotubes. PLoS One. 2014;9(1):e85721.

    Article  PubMed Central  PubMed  Google Scholar 

  53. Mitchell P, Marette A. Statin-induced insulin resistance through inflammasome activation: sailing between scylla and charybdis. Diabetes. 2014;63(11):3569–71.

    Article  CAS  PubMed  Google Scholar 

  54. Tamblyn R, Eguale T, Huang A, Winslade N, Doran P. The incidence and determinants of primary nonadherence with prescribed medication in primary care: a cohort study. Ann Intern Med. 2014;160:441–50.

    Article  PubMed  Google Scholar 

  55. Chi DM, Vansomphone SS, Liu IL, Cheetham TC, Green KR, Scott RD, et al. Adherence to statins and LDL-cholesterol goal attainment. Am J Manag Care. 2014;20:e105–12.

    PubMed  Google Scholar 

  56. Kones R. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther. 2011:5;325–80.

  57. Thavendiranathan P. Primary prevention of cardiovascular disease with statin therapy. Arch Intern Med. 2006;166:2307–13.

    Article  CAS  PubMed  Google Scholar 

  58. Baigent C, Keech A, Kearney PM, Cholesterol Treatment Trialists’ (CTT) Collaborators, et al. Efficacy and safety of cholesterol-lowering treatment. Lancet. 2005;366:1267–78.

    Article  CAS  PubMed  Google Scholar 

  59. Newman D. Statins given for 5 years for heart disease prevention (with known heart disease). The NNT Group; 2 Nov 2013. Available at: http://www.thennt.com/nnt/statins-for-heart-disease-prevention-with-known-heart-disease/. Accessed 19 Mar 2015.

  60. Newman D. Statins given for 5 years for heart disease prevention (without known heart disease). The NNT Group; 2 Nov 2013. Available at: http://www.thennt.com/nnt/statins-for-heart-disease-prevention-without-prior-heart-disease/. Accessed 19 Mar 2015.

  61. Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010;170:1024–31.

    Article  CAS  PubMed  Google Scholar 

  62. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(Suppl 2):S1–45.

    Article  PubMed  Google Scholar 

  63. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. 2013 ACC/AHA Guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(Suppl 2):S49–73.

    Article  PubMed  Google Scholar 

  64. Robinson JG. Evidence for statins in secondary and primary prevention. National Lipid Association, 2013 clinical lipid update agenda, understanding clinical guidelines and assessing CVD risk. 27 Feb 2013. Available at: www.lipid.org/sites/default/files/1-robinson_02_27_13.pdf. Accessed 19 Mar 2015.

  65. Myerson M, Rosenson RS. 2013 ACC/AHA guidelines: a guideline for the population—without evidence from the population. Cardiovas Drug Ther. 2014;28:203–4.

    Article  Google Scholar 

  66. D’Agostino RB Sr, Ansell BJ, Mora S, Krumholz HM. The guidelines battle on starting statins. N Engl J Med. 2014;370:1652–8.

    Article  PubMed  Google Scholar 

  67. Schutte JM, Rothaus CS, Adler JN. Clinical decisions. Starting statins: polling results. N Engl J Med. 2014;371:e6.

    Article  Google Scholar 

  68. Ioannidis JPA. More than a billion people taking statins? Potential implications of the new cardiovascular guidelines. JAMA. 2014;311:463–4.

    Article  CAS  PubMed  Google Scholar 

  69. Martin SS, Abel TT, Jones SR, Michos ED, Blumenthal RS, Blaha MJ. 2013 ACC/AHA cholesterol treatment guideline. What was done well and what could be done better J Am Coll Cardiol. 2014;63:2674–8.

    PubMed  Google Scholar 

  70. Amin NP, Martin SS, Blaha MJ, Nasir K, Blumenthal RS, Michose ED. Headed in the right direction but at risk for miscalculation. A critical appraisal of the 2013 ACC/AHA risk assessment guidelines. J Am Coll Cardiol. 2014;63:2789–94.

  71. Pencina MJ, Navar-Boggan AM, D’Agostino RB, Williams K, Neely B, Sniderman AD, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370:1422–31.

    Article  CAS  PubMed  Google Scholar 

  72. Brown WV. The art of prevention. J Clin Lipid. 2014;8:359–62.

    Article  Google Scholar 

  73. Expert Dyslipidemia Panel of the International Atherosclerosis Society. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia—full report. J Clin Lipid. 2014;8:29–60.

    Article  Google Scholar 

  74. Ray KK, Kastelein JJ, Boekholdt SM, Nicholls SJ, Khaw KT, Ballantyne CM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014;35:960–8.

    Article  PubMed  Google Scholar 

  75. Kavousi M, Leening MJG, Nanchen D, Greenland P, Graham IM, Steyerberg EW, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA. 2014;311:1416–23.

    Article  PubMed  Google Scholar 

  76. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet. 2013;382:1762–5.

    Article  PubMed  Google Scholar 

  77. DeFilippis AP, Young R, Carrubba CJ, McEvoy JW, Budoff MJ, Blumenthal RS, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort calibration and discrimination among CVD risk scores. Ann Intern Med. 2015;162:266–75.

    Article  PubMed  Google Scholar 

  78. Ridker PM, Cook NR. Comparing cardiovascular risk prediction scores. Ann Intern Med. 2015;162:313–4.

    Article  PubMed  Google Scholar 

  79. Hayward RA. Should family physicians follow the new ACC/AHA Cholesterol Treatment Guideline? Am Fam Phys. 2014;90:223–4.

    Google Scholar 

  80. Kones R, Rumana U. Current therapy of dyslipidemia: evolving roles of non-statin and newer drugs. Drugs. 2015. doi:10.1007/s40265-015-0429-3.

  81. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events. A meta-analysis of statin trials. J Am Coll Cardiol. 2014;64:485–94.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  82. Kataoka Y, St John J, Wolski K, Uno K, Puri R, Tuczu EM, et al. Atheroma progression in hyporesponders to statin therapy. Arterioscler Thromb Vasc Biol. 2015;35:990–5.

    Article  CAS  PubMed  Google Scholar 

  83. Johnson KM, Dowe DA. Accuracy of statin assignment using the 2013 AHA/ACC cholesterol guideline versus the 2001 NCEP ATP III guideline: correlation with atherosclerotic plaque imaging. J Am Coll Cardiol. 2014;64:910–9.

    Article  PubMed  Google Scholar 

  84. Pursnani A. The 2013 ACC/AHA cardiovascular prevention guidelines improve alignment of statin therapy with coronary atherosclerosis as detected by coronary computed tomography angiography [abstract no. 100]. In: Society of Cardiovascular Computed Tomography 2014 Annual Scientific Meeting; 11 Jul 2014; San Diego.

  85. Sugiyama T, Tsugawa Y, Tseng CH, Kobayashi Y, Shapiro MF. Different time trends of caloric and fat intake between statin users and nonusers among US adults: gluttony in the time of statins? JAMA Intern Med. 2014;174:1038–45.

    Article  PubMed Central  PubMed  Google Scholar 

  86. Lee DSH, Markwardt S, Goeres L, Lee CG, Eckstrom E, Williams C, et al. Statins and physical activity in older men: the Osteoporotic Fractures in Men Study. JAMA Intern Med. 2014;174:1263–70.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiometabolic Research Institute, 8181 Fannin St, Building 1, Unit 314, Houston, TX, 77054, USA

    Richard Kones & Umme Rumana

Authors
  1. Richard Kones
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Umme Rumana
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Kones.

Ethics declarations

Conflict of interest

Richard Kones and Umme Rumana have no conflicts of interest to declare.

Funding

No external funding was used for this work.

Appendix

Appendix

Box 1 Features of the 2013 ACC/AHA Assessment and Cholesterol Guidelines [62–64]
Full size table

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kones, R., Rumana, U. Current Treatment of Dyslipidemia: A New Paradigm for Statin Drug Use and the Need for Additional Therapies. Drugs 75, 1187–1199 (2015). https://doi.org/10.1007/s40265-015-0428-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0428-4

Keywords

Search

Navigation